Laurus Labs Ltd
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership
position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing.
Laurus employs 6500+ people, including around 1050+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]
- Market Cap ₹ 33,078 Cr.
- Current Price ₹ 613
- High / Low ₹ 646 / 385
- Stock P/E 132
- Book Value ₹ 79.2
- Dividend Yield 0.13 %
- ROCE 7.50 %
- ROE 5.43 %
- Face Value ₹ 2.00
Pros
Cons
- Stock is trading at 7.75 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of Nifty 500 BSE Momentum Index Nifty Pharma Nifty MidSmallcap 400 Nifty Smallcap 100
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
719 | 1,160 | 1,326 | 1,775 | 1,892 | 2,027 | 2,236 | 2,797 | 4,769 | 4,707 | 5,773 | 4,812 | 4,981 | |
573 | 951 | 1,121 | 1,402 | 1,478 | 1,618 | 1,884 | 2,226 | 3,258 | 3,421 | 4,292 | 4,062 | 4,161 | |
Operating Profit | 145 | 209 | 205 | 372 | 414 | 409 | 352 | 571 | 1,511 | 1,286 | 1,482 | 751 | 821 |
OPM % | 20% | 18% | 15% | 21% | 22% | 20% | 16% | 20% | 32% | 27% | 26% | 16% | 16% |
5 | 9 | 34 | 4 | 32 | 28 | 15 | 5 | 26 | 20 | 16 | 47 | 52 | |
Interest | 41 | 64 | 106 | 111 | 97 | 75 | 86 | 88 | 66 | 96 | 146 | 151 | 176 |
Depreciation | 23 | 33 | 61 | 86 | 104 | 121 | 161 | 184 | 197 | 235 | 301 | 345 | 360 |
Profit before tax | 86 | 121 | 72 | 180 | 245 | 241 | 121 | 304 | 1,275 | 975 | 1,051 | 301 | 338 |
Tax % | -2% | 20% | -2% | 19% | 18% | 28% | 22% | 12% | 25% | 23% | 28% | 26% | |
88 | 97 | 74 | 145 | 200 | 173 | 95 | 267 | 956 | 750 | 760 | 224 | 250 | |
EPS in Rs | 11.58 | 12.64 | 9.47 | 18.36 | 3.78 | 3.27 | 1.78 | 5.00 | 17.82 | 13.96 | 14.12 | 4.15 | 4.63 |
Dividend Payout % | 0% | 0% | 0% | 2% | 8% | 9% | 17% | 10% | 11% | 14% | 14% | 19% |
Compounded Sales Growth | |
---|---|
10 Years: | 15% |
5 Years: | 17% |
3 Years: | 0% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 19% |
3 Years: | -38% |
TTM: | 22% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 57% |
3 Years: | 1% |
1 Year: | 56% |
Return on Equity | |
---|---|
10 Years: | 18% |
5 Years: | 20% |
3 Years: | 16% |
Last Year: | 5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 15 | 15 | 16 | 16 | 106 | 106 | 106 | 107 | 107 | 107 | 108 | 108 | 108 |
Reserves | 182 | 281 | 645 | 790 | 1,250 | 1,407 | 1,484 | 1,709 | 2,605 | 3,281 | 3,949 | 4,099 | 4,162 |
355 | 605 | 888 | 1,081 | 808 | 947 | 1,009 | 1,051 | 1,411 | 1,653 | 1,714 | 2,110 | 2,341 | |
150 | 372 | 344 | 342 | 509 | 547 | 718 | 872 | 1,502 | 1,567 | 1,187 | 1,351 | 1,478 | |
Total Liabilities | 701 | 1,273 | 1,893 | 2,229 | 2,673 | 3,008 | 3,318 | 3,739 | 5,625 | 6,609 | 6,958 | 7,667 | 8,088 |
236 | 499 | 801 | 1,014 | 1,193 | 1,448 | 1,599 | 1,694 | 1,818 | 2,186 | 2,884 | 3,036 | 2,906 | |
CWIP | 73 | 116 | 107 | 70 | 143 | 163 | 107 | 67 | 324 | 755 | 357 | 156 | 255 |
Investments | 0 | 0 | 19 | 26 | 51 | 52 | 58 | 58 | 319 | 362 | 384 | 635 | 635 |
393 | 658 | 966 | 1,119 | 1,286 | 1,345 | 1,554 | 1,920 | 3,164 | 3,306 | 3,333 | 3,841 | 4,292 | |
Total Assets | 701 | 1,273 | 1,893 | 2,229 | 2,673 | 3,008 | 3,318 | 3,739 | 5,625 | 6,609 | 6,958 | 7,667 | 8,088 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
88 | 121 | -59 | 197 | 321 | 369 | 293 | 345 | 694 | 823 | 882 | 659 | |
-124 | -312 | -406 | -315 | -282 | -417 | -257 | -217 | -900 | -837 | -735 | -757 | |
34 | 203 | 486 | 90 | -47 | 49 | -37 | -127 | 243 | 15 | -185 | 139 | |
Net Cash Flow | -2 | 12 | 21 | -27 | -8 | 0 | -0 | 0 | 38 | 2 | -39 | 41 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 80 | 61 | 78 | 91 | 108 | 100 | 112 | 102 | 98 | 98 | 94 | 124 |
Inventory Days | 138 | 165 | 210 | 177 | 184 | 199 | 201 | 233 | 257 | 279 | 211 | 258 |
Days Payable | 117 | 114 | 101 | 91 | 110 | 106 | 144 | 157 | 194 | 140 | 90 | 151 |
Cash Conversion Cycle | 101 | 112 | 187 | 177 | 183 | 193 | 169 | 177 | 161 | 237 | 216 | 231 |
Working Capital Days | 93 | 48 | 119 | 117 | 126 | 124 | 116 | 119 | 127 | 140 | 138 | 175 |
ROCE % | 27% | 25% | 15% | 17% | 17% | 14% | 8% | 14% | 38% | 23% | 22% | 8% |
Documents
Announcements
-
Corrigendum To ''Intimation Of Grant Of Stock Options To The Eligible Employees'' Dated 28.03.2025
1d - Correction in trading date for stock options.
-
Announcement under Regulation 30 (LODR)-Acquisition
1d - Acquisition of 26% stake in Kurnool Renewables for INR 35 Crores.
-
Intimation Of Re-Appointment Of Executive Directors Of The Company Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
1d - Re-appointment of CEO and CFO for Laurus Labs.
-
Intimation Of Grant Of Stock Options To The Eligible Employees
1d - Grant of stock options to eligible employees.
-
Closure of Trading Window
2d - Closure of trading window from April 1, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
Concalls
-
Jan 2025Transcript PPT REC
-
Jan 2025TranscriptNotesPPT
-
Oct 2024TranscriptPPTREC
-
Oct 2024TranscriptNotesPPT REC
-
Jul 2024Transcript PPT REC
-
Apr 2024Transcript PPT REC
-
Jan 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Oct 2023Transcript PPT
-
Aug 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Mar 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Dec 2020Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
May 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Nov 2019Transcript PPT
-
Aug 2019Transcript PPT
-
May 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018Transcript PPT
-
Jan 2018Transcript PPT
-
Nov 2017Transcript PPT
-
Aug 2017TranscriptNotesPPT
-
May 2017Transcript PPT
-
Feb 2017Transcript PPT
Business Segments
1) Generic API (46% in 9M FY25 vs 41% in FY22): [1] [2] The company has one of the largest HiPotent API manufacturing capacities in India and is the world's leading third-party supplier of antiretroviral APIs. Its portfolio includes antiretrovirals, oncology, steroids, hormones, and cardiovascular APIs, serving global generic pharmaceutical companies. Segment revenue declined by 3% YoY in 9M FY25 due to ARV capacity reallocation towards high-yield, long-term business opportunities. [3] [1]